Header graphic for print
Dangerous Drugs & Medical Devices News & Commentary on Prescription Drug & Medical Device Lawsuits

Category Archives: Drugs

Subscribe to Drugs RSS Feed

Depakote raises risk for birth defects 2- to 4-fold

Posted in Depacon / Depakene / Depakote

In recent years, dozens of studies have linked prenatal exposure to the antiepileptic drugs containing valproate (Depacon, Depakene, and Depakote) with birth defects including spina bifida, and developmental disorders such as Autism.  Since the manufacturer of these drugs, Abbott Laboratories, failed time and again to warn women of these risks, Depacon birth defect lawsuits have… Continue Reading

Huge increase in birth defect risk with prenatal Depacon, AED exposure

Posted in Depacon / Depakene / Depakote

Titled “Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study.”, a study by K. Wide et al. (2004) further demonstrates knowledge in the medical community that in utero exposure to antiepileptic drugs (AEDs) containing valproate (Depacon, Depakene, Depakote, and others) is linked… Continue Reading

Offspring maladaptive with in utero SSRI epxosure

Posted in SSRI Birth Defects

Today, looking through PubMed Health, a medical literature database curated by the United States National Library of Medicine and The National Institutes of Health, I found another article linking poor neonatal outcomes and  to birth defects prenatal exposure to maternal selective serotonin reuptake inhibitor drugs (SSRIs).  This article, titled “Developmental effects of SSRIs: lessons learned… Continue Reading

2003 – In Utero AED Exposure Linked to Birth Defects Far Above Background Rate

Posted in Depacon / Depakene / Depakote

In September, 2003, a team from St. Vincent’s Hospital (Melbourne, Australia) published a piece in Journal of Clinical Neuroscience titled “The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months.”  That article, by F.J. Vajda et al., further explored the risks of prenatal exposure to antiepileptic drugs containing valproate, such as Depacon, Depakene,… Continue Reading

1999 – Researchers find Depacon, Depakene, and Depakote linked to major congenital abnormalities

Posted in Depacon / Depakene / Depakote

Published in a 1999 edition of Annals of Neurology, an article by E.B. Samrén et al. titled “Antiepileptic drug regimens and major congenital abnormalities in the offspring.” provides important insight into the risks of prenatal exposure to antiepileptic drugs (AEDs), something that has been demonstrated to greatly increase the rate of spina bifida, other neurological… Continue Reading

Prenatal exposure to Depacon, Depakene, Depakote linked to lower intelligence in children

Posted in Depacon / Depakene / Depakote

Over the past ten years or so, dozens of studies have been published linking prenatal exposure to the antiepileptic drugs Depacon, Depakene, and Depakote (Abbott Laboratories, Inc.) with birth defects.  Here, I will summarize one such study, published by R. Banach and a team from McMaster University in Ontario Canada.  This study was titled “Long-term… Continue Reading

1997 – Team finds Depacon / Depakene / Depakote to lift malformation risk up to 700%

Posted in Depacon / Depakene / Depakote

Back in 1997, a team of Dutch medical researchers led by E.B. Samrén published an article titled “Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy.” in Epilepsia.  That article aimed to “To quantify the risks of intrauterine antiepileptic drug… Continue Reading

Birth defects risk 2-3 times higher with Depacon exposure

Posted in Depacon / Depakene / Depakote

From a team of Swedish researchers, an article appearing in the November, 2009 edition of Neurologic Clinics titled “Teratogenic effects of antiepileptic medications.” provides important insight into the connection between prenatal exposure to epilepsy drugs Depacon, Depakene, and Depakote and cardiovascular and neurological birth defects.  Because of a failure to warn, class-action Depacon lawsuits have… Continue Reading

2011 – Depakote only drug to lift birth defect risk in polytherapy

Posted in Depacon / Depakene / Depakote

A study titled “Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations.” by L.B. Holmes and a team from MassGeneral Hospital for Children (Boston, MA) published in the October, 2011 edition of Archives of Neurology further explores the link between in utero exposure to epilepsy drugs containing valproate (Depacon and other drugs by… Continue Reading

New England Journal of Medicine: Depacon Causes Defects, Decreased Cognitive Function

Posted in Depacon / Depakene / Depakote

Titled “Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs.”, an article by K.J. Meador and a team from Emory University published in the April, 2009 edition of New England Journal of Medicine provides further insight into the adverse effects of prenatal exposure to antiepileptic drugs containing valproate, the active chemical… Continue Reading

Depacon, Depakote, and Depakene carry risk for birth defects at 6.7%

Posted in Depacon / Depakene / Depakote

In February of this year, E. Campbell and a team from Royal Victoria Hospital (Belfast, UK) published a piece in Journal of Neurology, Neurosurgery, and Psychiatry titled “Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers.” further demonstrating the link between exposure to maternal epilepsy… Continue Reading

Reduced cognitive ability linked to prenatal Depacon / Depakene / Depakote exposure

Posted in Depacon / Depakene / Depakote

In March, 2013, a medical research team led by K.J. Meador published an article in Lancet Neurology titled “Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.”.  This team from Emory University (Atlanta) aimed to “We aimed to assess effects of commonly used antiepileptic drugs on cognitive… Continue Reading

Depakote linked to birth defects, poor neonatal development

Posted in Depacon / Depakene / Depakote

In recent years, a number of independent medical research teams have determined that prenatal exposure to antiepileptic drugs branded Depacon, Depakene, and Depakote is linked to increased risk for birth defects.  Here, I will discuss research from one such team led by G. Veiby of The University of Bergen, Norway, specifically, an article titled “Pregnancy,… Continue Reading

Increased risk for neonatal morbidity linked to prenatal SSRI exposure

Posted in SSRI Birth Defects

In October, 2012, a team of Swedish researchers (University of Lund) led by B. Källén published an article in Journal of Clinical Psychopharmacology titled “Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy.”, exploring the range of neonatal complications linked to… Continue Reading

2013 – More researchers find serious risks with antidepressants in pregnancy

Posted in Prozac Birth Defects, SSRI Birth Defects

Titled “The risks of selective serotonin reuptake inhibitor use in infertile women: a review of the impact on fertility, pregnancy, neonatal health and beyond.”, a piece appearing in the January, 2013 edition of Human Reproduction by A.D. Domar and a team from Harvard Medical School provides important insight into the link between gestational exposure to… Continue Reading

Heart defects linked to prenatal Prozac exposure

Posted in Prozac Birth Defects, SSRI Birth Defects

In July, 2008, a team of researchers from The Netherlands led by CW Noorlander published a study titled “Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities.” in PLoS One.  This article delves further into the link between prenatal exposure to a mother’s selective serotonin reuptake inhibitor drug… Continue Reading

SSRIs in pregnancy linked to increased weight later in child’s life

Posted in SSRI Birth Defects

A 2012 in Reproductive Toxicology by L.E. Grzeskowiak at a team from University of South Australia  (Adelaide) titled “Long term impact of prenatal exposure to SSRIs on growth and body weight in childhood: evidence from animal and human studies.” explores the link between a baby’s exposure to maternal selective serotonin reuptake inhibitor drugs (SSRIs) and… Continue Reading

Another study links autism and maternal use of SSRI drugs in pregnancy

Posted in SSRI Birth Defects

A 2011 article in Archives of General Psychiatry by L.A. Croen and a team of researchers from Kaiser Permanente (a large healthcare company), titled “Antidepressant use during pregnancy and childhood autism spectrum disorders.” examines the relationship between gestational exposure to selective serotonin reuptake inhibitor drugs like Prozac, Zoloft, and Paxil and developmental disorders like autism… Continue Reading

Research highlights heart defects coupled with prenatal SSRI exposure

Posted in SSRI Birth Defects

Published in an August 2012 edition of Early Human Development, an article by K. Lim et al. titled “Third trimester fetal pulmonary artery Doppler blood flow velocity characteristics following prenatal selective serotonin reuptake inhibitor (SSRI) exposure.” further examines the risk for birth defects like persistent pulmonary hypertension of the newborn (PPHN) after exposure to maternal… Continue Reading

Study Shows: Drugs, not maternal illness, increase risk for poor neonatal development

Posted in SSRI Birth Defects

Today, while reading through PubMed, an amazing database of medical literature provided by the United States National Library of Medicine and The National Institutes of Health, I found an article dating back to 2003 titled “Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy.” originally appearing in The Journal… Continue Reading

2012 – Increased risk for poor birth outcomes with SSRI exposure

Posted in SSRI Birth Defects

Titled “Infant and childhood neurodevelopmental outcomes following prenatal exposure to selective serotonin reuptake inhibitors: overview and design of a Finnish Register-Based Study (FinESSI).”, an article by a team of prominent SSRI-birth defect researchers led by H. Malm (2012) published in BMC Psychiatry makes great strides in elucidating the range of adverse effects of prenatal exposure… Continue Reading

2005 – Late exposure to SSRIs in pregnancy risks negative consequences

Posted in SSRI Birth Defects

Titled “Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant.”, a 2005 Drug Safety article by H. Nordeng and a team from The University of Oslo (Norway) explores the effects of late pregnancy exposure to selective serotonin reuptake inhibitor drugs (SSRIs).  In the past two decades, droves of… Continue Reading

Study links SSRI exposure with smaller head circumference

Posted in SSRI Birth Defects

In March, 2012, G. Dubnov-Raz and a team of Israeli researchers published an article in Early Human Development titled “Maternal use of selective serotonin reuptake inhibitors during pregnancy and neonatal bone density.” that explores negative consequences of prenatal exposure to selective serotonin reuptake inhibitor drugs (SSRIs).  To-date, scores of peer-reviewed scientific studies have demonstrated that… Continue Reading

2013 – Developmental, social problems in children with prenatal SSRI exposure

Posted in SSRI Birth Defects

A Psychopharmacology article published last summer by T.L Gur and a team from the Perelman School of Medicine (University of Pennsylvania) titled “Central nervous system effects of prenatal selective serotonin reuptake inhibitors: sensing the signal through the noise.” reviews the consequences on the central nervous system (CNS) of prenatal exposure to selective serotonin reuptake inhibitor… Continue Reading